M. Kucuk Et Al. , "Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy," JOURNAL OF INFECTION AND CHEMOTHERAPY , no.7, pp.673-677, 2023
Kucuk, M. Et Al. 2023. Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy. JOURNAL OF INFECTION AND CHEMOTHERAPY , no.7 , 673-677.
Kucuk, M., Heybeli, C., Ozturk, M. C., Ergun, B., Yakar, M. N., Gokmen, A. N., ... Comert, B.(2023). Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy. JOURNAL OF INFECTION AND CHEMOTHERAPY , no.7, 673-677.
Kucuk, Murat Et Al. "Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy," JOURNAL OF INFECTION AND CHEMOTHERAPY , no.7, 673-677, 2023
Kucuk, Murat Et Al. "Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy." JOURNAL OF INFECTION AND CHEMOTHERAPY , no.7, pp.673-677, 2023
Kucuk, M. Et Al. (2023) . "Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy." JOURNAL OF INFECTION AND CHEMOTHERAPY , no.7, pp.673-677.
@article{article, author={Murat Kucuk Et Al. }, title={Dexmedetomidine may reduce the risk of acute kidney injury development in critically ill patients during colistin therapy}, journal={JOURNAL OF INFECTION AND CHEMOTHERAPY}, year=2023, pages={673-677} }